Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2024-05-29 00:00:00 ET · period of report 2024-05-24 · accession 0000875320-24-000160 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-05-29 | 2024-05-24 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | S - Sale+OE | $457.00 | -1,565 | 121.4K | -1% | -$715.2K |
| D | 2024-05-29 | 2024-05-24 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | M - OptEx | $187.53 | +1,565 | 122.9K | +1% | +$293.5K |
| D | 2024-05-29 | 2024-05-24 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | M - OptEx | $0.00 | -1,565 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-24 | S | D | 1,565 | $457.00 | 121,374 | D | — | — | |
| 2 | Common | Common Stock | 2024-05-24 | M | A | 1,565 | $187.53 | 122,939 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2024-05-24 | M | D | 1,565 | $0.00 | 0 | D | $187.53 · — to 2029-02-05 | 1,565 Common Stock | (F2) Fully vested. |